Resiquimod is primarily used in immunology and dermatology due to its potent immune-stimulating properties. It activates the body's innate immune response by targeting toll-like receptors TLR7 and TLR8, making it a candidate for treating viral infections and certain skin conditions. It has been investigated in topical formulations for the treatment of genital herpes and other mucosal viral infections due to its ability to enhance local antiviral defenses. Additionally, resiquimod is being studied in cancer immunotherapy, where it acts as an adjuvant to boost immune recognition of tumors, particularly in skin cancers like melanoma. Its role in vaccine development is also explored, as it can enhance the immune response to antigens. Due to its strong immunomodulatory effects, it is used mainly in clinical research and experimental therapies.